ArticleEBioMedicine2021
Prospective multicenter evaluation of real time PCR Kit prototype for early diagnosis of congenital Chagas disease.
Article in EBioMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Molecular diagnosis of Chagas disease: a systematic review and meta-analysis.Infectious diseases of poverty · 2023Pooled it
- Consensus framework for developing a target product profile of real-time PCR in Chagas disease therapeutic monitoring.PLoS neglected tropical diseases · 2026Article
- Current and emerging molecular diagnostic approaches in the detection of human parasites.Parasitology research · 2026Review
- Placental transcriptome profiling in congenital Chagas disease: gene networks associated with transmission.Frontiers in cellular and infection microbiology · 2026Article
- Quantitative Real-Time PCR for Trypanosoma cruzi Infection Diagnosis and Treatment Response Monitoring of Patients with Chagas Disease.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Non-Coding RNAs as Emerging Biomarkers in Leishmaniasis and Chagas Disease.Tropical medicine and infectious disease · 2025Review
- Mass spectrometry-based discovery and diagnostic validation of T. cruzi antigens in the urine of congenitally infected Chagas Disease patients.PLoS neglected tropical diseases · 2025Article
- Congenital Chagas disease: A cohort study to assess molecular diagnostic methods at the Chagas disease national reference center of Argentina.PLoS neglected tropical diseases · 2025Article
- Retrospect, advances and challenges in Chagas disease diagnosis: a comprehensive review.Lancet regional health. Americas · 2024Review
- Article
- Usefulness of polymerase chain reaction tests in Chagas disease studies.Frontiers in parasitology · 2024Article
- Subunit nanovaccine elicited T cell functional activation controls Trypanosoma cruzi mediated maternal and placental tissue damage and improves pregnancy outcomes in mice.NPJ vaccines · 2023Article
- Validation of the NAT Chagas IVD Kit for the Detection and Quantification ofLife (Basel, Switzerland) · 2023Article
- Combination of ultra-rapid DNA purification (PURE) and loop-mediated isothermal amplification (LAMP) for rapid detection of Trypanosoma cruzi DNA in dried blood spots.PLoS neglected tropical diseases · 2023Article
- Effects of Acute and Chronic Trypanosoma cruzi Infection on Pregnancy Outcomes in Mice: Parasite Transmission, Mortality, Delayed Growth, and Organ Damage in Pups.The American journal of pathology · 2023Article
- Clinical use of molecular methods forFrontiers in parasitology · 2023Article
- Laboratory diagnosis ofFrontiers in parasitology · 2023Review
- Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital Trypanosoma cruzi Infection.Clinical microbiology reviews · 2022Review
- Diagnostic Accuracy of Two Molecular Tools for Diagnosis of Congenital Chagas Disease.Molecular diagnosis & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent algorithm for Congenital Chagas Disease (cCD) diagnosis is unsatisfactory due to low sensitivity of the parasitological methods. Moreover, loss to follow-up precludes final serodiagnosis after nine months of life in many cases. A duplex TaqMan qPCR kit for Trypanosoma cruzi DNA amplification was prospectively evaluated in umbilical cord (UCB) and peripheral venous blood (PVB) of infants born to CD mothers at endemic and non-endemic sites of Argentina.
methodsWe enrolled and followed-up 370 infants; qPCR was compared to gold-standard cCD diagnosis following studies of diagnostic accuracy guidelines.
findingsFourteen infants (3·78%) had cCD. The qPCR sensitivity and specificity were higher in PVB (72·73%, 99·15% respectively) than in UCB (66·67%, 96·3%). Positive and negative predictive values were 80 and 98·73% and 50 and 98·11% for PVB and UCB, respectively. The Areas under the Curve (AUC) of ROC analysis for qPCR and micromethod (MM) were 0·81 and 0·67 in UCB and 0·86 and 0·68 in PVB, respectively. Parasitic loads ranged from 37·5 to 23,709 parasite equivalents/mL. Discrete typing Unit Tc V was identified in five cCD patients and in six other cCD cases no distinction among Tc II, Tc V or Tc VI was achieved.
interpretationThis first prospective field study demonstrated that qPCR was more sensitive than MM for early cCD detection and more accurate in PVB than in UCB. Its use, as an auxiliary diagnostic tool to MM will provide more accurate records on cCD incidence.
fundingFITS SALUD 001-CHAGAS (FONARSEC, MINCyT, Argentina) to the Public-Private Consortium (INGEBI-CONICET, INP-ANLIS MALBRAN and Wiener Laboratories); ERANET-LAC-HD 328 to AGS and PICT 2015-0074 (FONCYT, MinCyT) to AGS and FA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.